Background In the phase 1–2 portion of an adaptive trial, REGEN-COV, a combination of the
monoclonal antibodies casirivimab and imdevimab, reduced the viral load and number of …

Importance Easy-to-administer anti–SARS-CoV-2 treatments may be used to prevent
progression from asymptomatic infection to symptomatic disease and to reduce viral carriage. …

Background REGEN-COV antibody cocktail (casirivimab with imdevimab) rapidly reduced
viral load and decreased medically-attended visits in the phase 1/2 portion of this trial; REGEN…

Importance The monoclonal antibody combination of casirivimab and imdevimab reduced
viral load, hospitalization, or death when administered as a 1200-mg or greater intravenous (IV…

Background The monoclonal antibody combination casirivimab and imdevimab (REGEN-COV
® ) reduced viral load, hospitalisation, or death when administered 1:1 as an intravenous (…

Background: The monoclonal antibody combination casirivimab and imdevimab (REGEN-COV
(R)) reduced viral load, hospitalisation, or death when administered 11 as an intravenous …

Substantial progresshas been made in therapeutics for nonhospitalizedpatientswithCOVID-19,
butsupplyofand access to treatment remain limited. This Viewpoint summarizes currently …

The phases of SARS-CoV-2 infection may be viewed along a spectrum. 1 Following
exposure, patients may have asymptomatic infection in which they test positive for the virus by …

There are several approved treatments for coronavirus disease 2019 (COVID-19) in hospitalized
patients but few for patients who are not sick enough to be hospitalized. Monoclonal …

… ; Lilia Roque-Guerrero; Ana Gomez Ramirez; Javier Capote; Gisel Paz; Michael Paasche-Orlow;
Julien Dedier; Sanjay Vadgama; Ramachandra Patak; Nicolas Chronos; Cary Hefty; …